Zev A Wainberg - JoVE Visualize

Showing results (21-30 of 131) with videos related to

Pageof 14

Sort By:

Investigational New Drugs|January 8, 2014

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancerCarolyn D Britten, Alex A Adjei, Robert Millham, et al.

Future Oncology (London, England)|August 3, 2022

Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II studyJohn H Strickler, Antonio Cubillo, Jin-Tung Liang, et al.

Clinical Colorectal Cancer|October 1, 2013

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerZev A Wainberg, Wells A Messersmith, Parvin F Peddi, et al.

Urologic Oncology|December 17, 2008

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell linesHervé Wallerand, Ying Cai, Zev A Wainberg, et al.

BMC Cancer|January 17, 2012

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot studyCarolyn D Britten, Antoinette S Gomes, Zev A Wainberg, et al.

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 27, 2016

CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic CancerJennifer L Williams, Brian E Kadera, Andrew H Nguyen, et al.

Future Oncology (London, England)|May 4, 2026

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trialMaen Abdelrahim, Gazala Khan, Hassan Hatoum, et al.

British Journal of Clinical Pharmacology|March 2, 2022

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairmentCen Guo, Yanke Yu, Jayeta Chakrabarti, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant SettingZev A Wainberg, Jipan Xie, Adriana Valderrama, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)Manish A Shah, Gyorgy Bodoky, Alexander Starodub, et al.

Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:

Pageof 14

Investigational New Drugs|January 8, 2014

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancerCarolyn D Britten, Alex A Adjei, Robert Millham, et al.

Future Oncology (London, England)|August 3, 2022

Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II studyJohn H Strickler, Antonio Cubillo, Jin-Tung Liang, et al.

Clinical Colorectal Cancer|October 1, 2013

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancerZev A Wainberg, Wells A Messersmith, Parvin F Peddi, et al.

Urologic Oncology|December 17, 2008

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell linesHervé Wallerand, Ying Cai, Zev A Wainberg, et al.

BMC Cancer|January 17, 2012

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot studyCarolyn D Britten, Antoinette S Gomes, Zev A Wainberg, et al.

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 27, 2016

CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic CancerJennifer L Williams, Brian E Kadera, Andrew H Nguyen, et al.

Future Oncology (London, England)|May 4, 2026

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trialMaen Abdelrahim, Gazala Khan, Hassan Hatoum, et al.

British Journal of Clinical Pharmacology|March 2, 2022

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairmentCen Guo, Yanke Yu, Jayeta Chakrabarti, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant SettingZev A Wainberg, Jipan Xie, Adriana Valderrama, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)Manish A Shah, Gyorgy Bodoky, Alexander Starodub, et al.

Pageof 14